<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04115527</url>
  </required_header>
  <id_info>
    <org_study_id>HBP-RCT-003</org_study_id>
    <nct_id>NCT04115527</nct_id>
  </id_info>
  <brief_title>Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma.</brief_title>
  <official_title>A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether para-aortic lymph nodes(No.16) should be
      included in the lymphadenectomy during the pancreatoduodenectomy in order to improve the
      long-term survival of patients with pancreatic head ductal adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is now raised to the 7th leading cause of death. Surgical resection seems
      to be the unique curative therapy for pancreatic cancer. The pancreaticoduodenectomy is
      widely performed for the patients with pancreatic head cancer in recent decades. The
      lymphadenectomy is an indispensible procedure. In 2014, the International Study Group for
      Pancreatic Surgery (ISGPS) recommended a standard lymphadenectomy should include lymph node
      stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a, and 17b. However, no consensus
      was reached on Lymph node 16 in particular 16b1. There was no stronge evidence available
      concerning the impact on survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year overall survival rate</measure>
    <time_frame>1 year post-operation</time_frame>
    <description>1 year overall survival rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3 years overall survival rate</measure>
    <time_frame>3 years post-operation</time_frame>
    <description>3 years overall survival rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5 years overall survival rate</measure>
    <time_frame>5 years post-operation</time_frame>
    <description>5 years overall survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>Within 90 days or before discharge</time_frame>
    <description>pancreatic fistula, bile leakage, haemorrhage, DGE, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1, 3 &amp; 5 years disease free survival rate</measure>
    <time_frame>1, 3 &amp; 5 years post-operation</time_frame>
    <description>1, 3 &amp; 5 years disease free survival rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Standard lymphadenectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard lymphadenectomy includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes harvested during the pancreaticoduodenectomy with CHILD's digestive reconstruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to the standard lymphadenectomy, para-aortic lymph nodes (No16) is included, in particular No 16b1 lymph nodes (Lymph nodes along the psterior side of the pancreas between the aorta and inferior vena cava).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extended Lymphadenectomy</intervention_name>
    <description>Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes</description>
    <arm_group_label>Extended lymphadenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Lymphadenectomy</intervention_name>
    <description>Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes</description>
    <arm_group_label>Standard lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic diagnosis of pancreatic ductal adenocarcinoma

          -  Signed the informed consents

        Exclusion Criteria:

          -  Pathologic diagnosis of other pancreatic cancers

          -  Pre-operative anti-cancer treatment

          -  Recurrence patients

          -  Patients with contraindication(hepatic/ respiratory/ renal dysfunction, etc )

          -  Pre operative exam: Total bilirubin more than 250Âµmol/L

          -  AJCC stage IV

          -  Operation non radical
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiancheng WANG, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Ruijin Pancreatic Disease Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weishen WANG, Dr</last_name>
    <phone>0086-(0)21-64370045</phone>
    <phone_ext>362362</phone_ext>
    <email>peanutswey@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weishen WANG</last_name>
      <phone>0086-(0)21-64370045</phone>
      <phone_ext>362362</phone_ext>
      <email>peanutswey@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Weishen WANG</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>RCT</keyword>
  <keyword>Standard lymphadenectomy</keyword>
  <keyword>Extended lymphadenectomy</keyword>
  <keyword>Pancreaticoduodenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

